In Brief: NeoPharm Broxine/Neomark-BU
Executive Summary
NeoPharm Broxine/Neomark-BU: Single NDA filed Dec. 27 for broxuridine for use as a radiation sensitizer in the treatment of malignant gliomas or brain tumors (Broxine) and for use as an in vivo prognostic test to measure tumor cell proliferation in breast cancer (Neomark-BU), the Lake Forest, Ill.-based company announces...